OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on USP <797> 2023 revision.
To answer DebRD_ATL: yes, I am on compounded sema from a 503B pharmacy.
Quick update: things are still going well. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏
Relevant to USP <797> 2023 revision impact — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 217 → 117 mg/dL, hsCRP 8.0 → 1.1 mg/L. All on tirzepatide for 9 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
100%. My provider said the same thing about USP <797> 2023.
Slightly tangential to USP <797> 2023 revision but Dr.SleepRoch reminded me — does anyone have experience combining this with metformin?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
Dr.PulmRoch said:Thank you all for the thoughtful replies on USP 2023 revision
This is exactly right. Dr.PulmRoch articulated what I have been trying to explain to my doctor for months. The USP <797> 2023 revision aspect is the most important factor.